Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)
Georgette M. Castanedo, Nicole Blaquière, Maureen H. Beresini et al. · Journal of Medicinal Chemistry · 2016
We report here structure-guided optimization of a novel series of NF-κB inducing kinase (NIK) inhibitors. Starting from a modestly potent, low molecular weight lead, activity was improved by designing a type 11/2 binding mode that accessed a back pocket past the methionine-471 gatekeeper. Divergent binding modes in NIK and PI3K were exploited to dampen PI3K inhibition while maintaining NIK inhibition within these series. Potent compounds were discovered that selectively inhibit the nuclear translocation of NF-κB2 (p52/REL-B) but not canonical NF-κB1 (REL-A/p50).
Cited by 59 works. doi:10.1021/acs.jmedchem.6b01363
Authors
- Georgette M. Castanedo
- Nicole Blaquière
- Maureen H. Beresini
- Brandon J. Bravo
- Hans D. Brightbill
- Jacob Chen
- Haifeng Cui
- Charles W. Eigenbrot
- Jianwen A. Feng
- Robert Godemann
- Emily B. Gogol
- S.G. Hymowitz
- Adam R. Johnson
- Nobuhiko Kayagaki
- Pawan Bir Kohli
- Kathleen Knüppel
- Joachim Kraemer
- Susan Krüger
- Pui L. Loke
References
- The influence of drug-like concepts on decision-making in medicinal chemistry
- Activation by IKKα of a Second, Evolutionary Conserved, NF-κB Signaling Pathway
- Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
- NF-κB-Inducing Kinase Regulates the Processing of NF-κB2 p100
- Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-κb-inducing kinase
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
- IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases